{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:13:23Z","timestamp":1792548803037,"version":"4.5.0"},"reference-count":131,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>Psoriasis is a chronic, debilitating, relapsing, inflammatory dermatosis, which affects approximately 2-3% of the population. The burgeoning research on pathogenesis of psoriasis has opened up new directions in management of this common condition. The introduction of biologics has given additional elements to the arsenal of psoriatic disease treatments. TNF-\u03b1 inhibitors, IL-12\/23 inhibitors, IL-17 inhibitors, CD-6 inhibitor proved highly efficient and have a good safety profile in numerous clinical trials. Biosimilar drugs are structurally almost similar to their reference biologic and are also made from living organism. Long-term follow-up and post-marketing surveillance are required to understand, long-term efficacy, adverse events of these powerful potent molecules.<\/jats:p>","DOI":"10.4103\/ijd.ijd_421_23","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T16:39:11Z","timestamp":1724949551000},"page":"282-295","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Biologics and Biosimilars in Psoriasis"],"prefix":"10.4103","volume":"68","author":[{"given":"Sk Shahriar","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"De","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudip","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashpal","family":"Manchanda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Farwaniya Hospital, Kuwait University, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250921","first-page":"489","article-title":"Biologics use in Indian psoriasis patients","volume":"7","author":"Rajagopalan","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"R2-20250921","first-page":"e55","article-title":"Off label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2)","volume":"56","author":"Graves","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R3-20250921","first-page":"191822","article-title":"Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway","volume":"32","author":"Madland","year":"2005","journal-title":"J Rheumatol"},{"key":"R4-20250921","first-page":"116","article-title":"Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis","volume":"58","author":"Perlmutter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R5-20250921","first-page":"45867","article-title":"Fatal PML associated with efalizumab therapy: Insights into integrin \u03b1L\u03b22 in JC virus control","volume":"78","author":"Schwab","year":"2012","journal-title":"Neurology"},{"key":"R6-20250921","first-page":"15965","article-title":"Manufacturing history of etanercept (Enbrel\u00ae): Consistency of product quality through major process revisions","volume":"10","author":"Hassett","year":"2018","journal-title":"MAbs"},{"key":"R7-20250921","first-page":"11524","article-title":"Infliximab for the treatment of plaque psoriasis","volume":"2","author":"Gall","year":"2008","journal-title":"Biologics"},{"key":"R8-20250921","first-page":"3757","article-title":"Adalimumab (HUMIRA): A review","volume":"2","author":"Scheinfeld","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"R9-20250921","first-page":"42231","article-title":"Golimumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"MAbs"},{"key":"R10-20250921","first-page":"10623","article-title":"Biocon's firstinclass antiCD6 mAb reaches the market","volume":"31","author":"Jayaraman","year":"2013","journal-title":"Nat Biotechnol"},{"key":"R11-20250921","first-page":"21621","article-title":"Ustekinumab","volume":"1","author":"Cingoz","year":"2009","journal-title":"MAbs"},{"key":"R12-20250921","first-page":"603","article-title":"Cosentyx (secukinumab): First IL17A antagonist receives FDA approval for moderatetosevere plaque psoriasis","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"R13-20250921","first-page":"8459","article-title":"Tildrakizumab: First global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"R14-20250921","first-page":"486","article-title":"British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005","volume":"153","author":"Smith","year":"2005","journal-title":"Br J Dermatol"},{"key":"R15-20250921","first-page":"1842","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"R16-20250921","first-page":"655","article-title":"The use of infliximab in dermatology","volume":"5","author":"Rott","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"R17-20250921","first-page":"342","article-title":"Biologic therapy in erythrodermic and pustular psoriasis","volume":"13","author":"Levin","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"R18-20250921","first-page":"417","article-title":"Efficacy and safety of biologics in erythrodermic psoriasis: A multicentre, retrospective study","volume":"167","author":"Viguier","year":"2012","journal-title":"Br J Dermatol"},{"key":"R19-20250921","first-page":"329","article-title":"A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: Evidence for efficacy and high incidence of biological autoimmunity","volume":"156","author":"Poulalhon","year":"2007","journal-title":"Br J Dermatol"},{"key":"R20-20250921","first-page":"828","article-title":"Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis","volume":"157","author":"Takahashi","year":"2007","journal-title":"Br J Dermatol"},{"key":"R21-20250921","first-page":"31 e1","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R22-20250921","first-page":"1367","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"R23-20250921","first-page":"1402","article-title":"Treatment of palmoplantar psoriasis with infliximab: A randomized, double-blind placebo-controlled study","volume":"25","author":"Bissonnette","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R24-20250921","first-page":"224","article-title":"Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year","volume":"58","author":"Rich","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R25-20250921","first-page":"81","article-title":"Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate","volume":"76","author":"Wu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R27-20250921","first-page":"345","article-title":"Treating psoriasis with adalimumab","volume":"4","author":"Alwawi","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R28-20250921","first-page":"133","article-title":"Adalimumab in the treatment of arthritis","volume":"3","author":"Mease","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"R29-20250921","first-page":"106","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R30-20250921","first-page":"3279","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R31-20250921","first-page":"882","article-title":"Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and\/or feet: Post hoc analysis of REACH","volume":"28","author":"Poulin","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R32-20250921","first-page":"AB220","article-title":"Levels of response of psoriasis patients with different baseline characteristics treated with etanercept","volume":"54","author":"Strober","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R33-20250921","first-page":"1627","article-title":"A Randomized Trial of Etanercept as Monotherapy for Psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"R34-20250921","first-page":"2014","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"R35-20250921","first-page":"1112","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: Primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R36-20250921","first-page":"302","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R37-20250921","first-page":"48","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R38-20250921","first-page":"2504","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R39-20250921","first-page":"1037","article-title":"A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis","volume":"123","author":"Kauffman","year":"2004","journal-title":"J Invest Dermatol"},{"key":"R40-20250921","first-page":"f5961","article-title":"Risk of moderate to advanced kidney disease in patients with psoriasis: Population based cohort study","volume":"347","author":"Wan","year":"2013","journal-title":"BMJ"},{"key":"R41-20250921","first-page":"1665","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"R42-20250921","first-page":"1675","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"R43-20250921","first-page":"780","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"R44-20250921","first-page":"296","article-title":"Clearance of annular pustular psoriasis with ustekinumab","volume":"27","author":"Schnabel","year":"2017","journal-title":"Eur J Dermatol"},{"key":"R45-20250921","first-page":"179","article-title":"Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis","volume":"24","author":"Au","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"R46-20250921","first-page":"96","article-title":"Ustekinumab in nail psoriasis: An open-label, uncontrolled, nonrandomized study","volume":"24","author":"Patsatsi","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"R47-20250921","first-page":"742","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R49-20250921","first-page":"309","article-title":"Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial","volume":"154","author":"Terui","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R50-20250921","first-page":"418","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R51-20250921","first-page":"1115","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"R52-20250921","first-page":"405","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R53-20250921","first-page":"650","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"R54-20250921","first-page":"576","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"R55-20250921","first-page":"649","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: A phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R56-20250921","first-page":"605","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"R57-20250921","first-page":"88","article-title":"Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: Results from a randomized phase II study","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"R58-20250921","first-page":"627","article-title":"Efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: Pooled analysis of four phase 3 studies","volume":"6","author":"Kircik","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R59-20250921","first-page":"124","article-title":"Secukinumab in the treatment of generalized pustular psoriasis: A case report","volume":"97","author":"Polesie","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"R60-20250921","first-page":"1439","article-title":"Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: A case series","volume":"178","author":"Weng","year":"2018","journal-title":"Br J Dermatol"},{"key":"R61-20250921","first-page":"e420","article-title":"Successful secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis","volume":"31","author":"Mugheddu","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R62-20250921","first-page":"60","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R63-20250921","first-page":"1496","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): A double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"R64-20250921","first-page":"27","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R65-20250921","first-page":"276","article-title":"Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis","volume":"53","author":"Shelton","year":"2019","journal-title":"Ann Pharmacother"},{"key":"R66-20250921","first-page":"1190","article-title":"Anti-interleukin17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"R67-20250921","first-page":"1148","article-title":"Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis","volume":"29","author":"Saeki","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R68-20250921","first-page":"355","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"key":"R69-20250921","first-page":"855","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R70-20250921","first-page":"33","article-title":"Ixekizumab in nail psoriasis","author":"Dattola","year":"2020","journal-title":"Dermatol Ther"},{"key":"R71-20250921","first-page":"282","article-title":"Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: Results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"28","author":"Reich","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"R72-20250921","first-page":"345","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"R73-20250921","first-page":"1014","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"key":"R74-20250921","first-page":"123","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R75-20250921","first-page":"1763","article-title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","volume":"29","author":"Langley","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R76-20250921","first-page":"192","article-title":"Support needed to involve psoriasis patients in treatment decisions: Survey of dermatologists","volume":"15","author":"Tan","year":"2011","journal-title":"J Cutan Med Surg"},{"key":"R77-20250921","first-page":"44","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"R78-20250921","first-page":"741","article-title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: Results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br J Dermatol"},{"key":"R79-20250921","first-page":"1318","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"R80-20250921","first-page":"185","article-title":"Brodalumab in psoriatic arthritis: Results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R81-20250921","first-page":"484","article-title":"Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study","volume":"71","author":"Krupashankar","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R82-20250921","first-page":"215","article-title":"Itolizumab - A humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis","volume":"8","author":"Menon","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4 Suppl","key":"R83-20250921","first-page":"25","article-title":"Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis","volume":"84","author":"Feldman","year":"2009","journal-title":"Cutis"},{"key":"R84-20250921","first-page":"878","article-title":"Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: Results of an open label trial","volume":"10","author":"Kircik","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"R85-20250921","first-page":"514","article-title":"Combining systemic retinoids with biologic agents for moderate to severe psoriasis","volume":"47","author":"Smith","year":"2008","journal-title":"Int J Dermatol"},{"key":"R86-20250921","first-page":"277","article-title":"Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort","volume":"23","author":"Dalaker","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R87-20250921","first-page":"934","article-title":"Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis","volume":"69","author":"D'Angelo","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R88-20250921","first-page":"2","article-title":"Effective treatment of etanercept and phototherapy-resistant psoriasis using the excimer laser","volume":"18","author":"Park","year":"2012","journal-title":"Dermatol Online J"},{"key":"R89-20250921","first-page":"313","article-title":"Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: A retrospective study","volume":"20","author":"AbuHilal","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"R90-20250921","first-page":"1029","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R91-20250921","first-page":"742","article-title":"The Budget Impact of Biosimilar Infliximab (Remsima\u00ae) for the Treatment of Autoimmune Diseases in Five European Countries","volume":"32","author":"Jha","year":"2015","journal-title":"Adv Ther"},{"key":"R92-20250921","first-page":"493","article-title":"Switching biologics in psoriasis - practical guidance and evidence to support","volume":"13","author":"Tsai","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R93-20250921","first-page":"118","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"R94-20250921","first-page":"273","article-title":"Efficacy and safety of switching to ixekizumab in etanercept non-responders: A subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3)","volume":"18","author":"Blauvelt","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl 1","key":"R95-20250921","first-page":"AB259","article-title":"Tildrakizumab, a selective anti-IL-23 monoclonal antibody, is effective in subjects with chronic plaque psoriasis who do not adequately respond to etanercept","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R96-20250921","first-page":"418","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R97-20250921","first-page":"576","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"R98-20250921","first-page":"114","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"R99-20250921","first-page":"306","article-title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: Subgroup analysis of two randomized phase III trials","volume":"180","author":"Langley","year":"2019","journal-title":"Br J Dermatol"},{"key":"R100-20250921","first-page":"213","article-title":"Switching from secukinumab to ACCEPTED MANUSCRIPT ustekinumab in psoriasis patients: Results from a multicenter experience","volume":"235","author":"Chiricozzi","year":"2019","journal-title":"Dermatology"},{"key":"R101-20250921","first-page":"1547","article-title":"Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: Results from a multicentre experience","volume":"180","author":"Conti","year":"2019","journal-title":"Br J Dermatol"},{"key":"R102-20250921","first-page":"421","article-title":"Successful intra-class switching among IL-17 antagonists: A multicentre, multinational, retrospective study","volume":"311","author":"Gasslitter","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"R103-20250921","first-page":"1646","article-title":"Network meta-analyses of systemic treatments for psoriasis: A critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis","volume":"137","author":"Ellis","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R103-20250921","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane database syst rev"},{"key":"R103-20250921","first-page":"282","volume":"180","year":"2019","journal-title":"Br J Dermatol"},{"key":"R104-20250921","first-page":"355","article-title":"Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response","volume":"33","author":"Sawyer","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R105-20250921","first-page":"381","article-title":"Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis","volume":"49","author":"Lu","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R106-20250921","first-page":"2534","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R107-20250921","first-page":"176","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R108-20250921","first-page":"1295","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R109-20250921","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R110-20250921","first-page":"279","article-title":"Safety of biologics in psoriasis","volume":"45","author":"Kamata","year":"2018","journal-title":"J Dermatol"},{"key":"R111-20250921","first-page":"261","article-title":"Antidrug antibodies in psoriasis: A systematic review","volume":"170","author":"Hsu","year":"2014","journal-title":"Br J Dermatol"},{"key":"R112-20250921","first-page":"258","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R113-20250921","first-page":"27","article-title":"Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R114-20250921","first-page":"422","article-title":"Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19","volume":"24","author":"Ni","year":"2020","journal-title":"Crit Care"},{"key":"R115-20250921","first-page":"497","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R116-20250921","first-page":"266","article-title":"Understanding SARS-CoV-2-mediated inflammatory responses: From mechanisms to potential therapeutic tools","volume":"35","author":"Fu","year":"2020","journal-title":"Virol Sin"},{"key":"R117-20250921","first-page":"420","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R118-20250921","first-page":"373","article-title":"The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: The Northern Italy experience","volume":"183","author":"Gisondi","year":"2020","journal-title":"Br J Dermatol"},{"key":"R119-20250921","first-page":"749","article-title":"Lack of evidence for an increased risk of severe COVID-19 in psoriasis patients on biologics: A cohort study from northeast Italy","volume":"21","author":"Piaserico","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R120-20250921","first-page":"558","article-title":"Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience","volume":"147","author":"Gisondi","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R121-20250921","first-page":"1581","article-title":"The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy","volume":"33","author":"Ciechanowicz","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R122-20250921","first-page":"e14691","article-title":"The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul","volume":"34","author":"Polat","year":"2021","journal-title":"Dermatol Ther"},{"key":"R123-20250921","first-page":"e676","article-title":"Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R124-20250921","first-page":"1425","article-title":"COVID-19 and systemic therapies in psoriasis: Experience of a tertiary hospital in Madrid","volume":"59","author":"Fulgencio-Barbarin","year":"2020","journal-title":"Int J Dermatol"},{"key":"R125-20250921","first-page":"513","article-title":"Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. J","volume":"84","author":"Baniandr\u00e9s-Rodr\u00edguez","year":"2021","journal-title":"Am Acad Dermatol"},{"key":"R126-20250921","first-page":"e14700","article-title":"Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience","volume":"34","author":"Polat Ekinci","year":"2021","journal-title":"Dermatol Ther"},{"key":"R127-20250921","first-page":"e13475","article-title":"Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration","volume":"33","author":"Damiani","year":"2020","journal-title":"Dermatol Ther"},{"key":"R128-20250921","first-page":"e14516","article-title":"Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone","volume":"33","author":"Brazzelli","year":"2020","journal-title":"Dermatol Ther"},{"key":"R129-20250921","first-page":"13","article-title":"Biologic therapies, psoriasis, and COVID-19: Our experience at the psoriasis unit of the university of naples federico II","volume":"237","author":"Camela","year":"2021","journal-title":"Dermatology"},{"key":"R130-20250921","first-page":"307","article-title":"Managing cutaneous immune-mediated diseases during the COVID-19 pandemic","volume":"21","author":"Torres","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R131-20250921","first-page":"e13490","article-title":"Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits","volume":"33","author":"Conforti","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_421_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:20Z","timestamp":1787067440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_421_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":131,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_421_23","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}